SAN DIEGO , Sept. 29, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced an update on the proposed design of its planned registration-directed clinical trial in first-line pancreatic ductal adenocarcinoma (PDAC). The Company is currently scheduled to meet with the U.S. Food and Drug Administration (FDA) in... Read More

SAN DIEGO , Sept. 16, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced updates on enrollment progress, U.S. site expansion, and expected data readouts from the ongoing GOBLET trial evaluating pelareorep in gastrointestinal cancers. The study is supported in part by a grant from the Pancreatic Cancer Action... Read More

In KRAS mutant 2L mCRC, pelareorep delivers prolonged survival benefit with a median PFS and median OS approximately 2.5x the current standard of care Translational data from multiple studies confirm pelareorep replication in CRC tumors and immune activation Company to define regulatory pathway and advance potential IST in KRAS mutant CRC patient population SAN DIEGO , Sept. 8, 2025 /CNW/ -- Oncolytics Biotech ® Inc.... Read More

Data continue to demonstrate a favorable safety profile for pelareorep across multiple indications and in combination with multiple treatments Updated clinical data now account for over 300 gastrointestinal cancer patients, including patients from the GOBLET study, demonstrating pelareorep's potential as a platform therapy Intravenously administered pelareorep continues to show clinical benefit SAN DIEGO , Sept. 2, 2025... Read More

SAN DIEGO , Aug. 28, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, will participate in two investor conferences next month. CEO Jared Kelly will be meeting with institutional investors at the H.C. Wainwright 27 th Annual Global Investment Conference and the Lake Street Capital Markets 9 th Annual Best Ideas Growth... Read More

SAN DIEGO , Aug. 11, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either... Read More

Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions Translational data further elucidate pelareorep's mechanism of action and ability to prime the tumor microenvironment for treatment Commitment to... Read More

SAN DIEGO , Aug. 8, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that the common shares in the capital of the Company (the "Shares") will be voluntarily delisted from the Toronto Stock Exchange ("TSX") at the close of markets on August 22, 2025 , pursuant to the Company's application for... Read More

The management team will provide a brief corporate update after the formal portion of the shareholder meeting SAN DIEGO and CALGARY, AB , Aug. 5, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that its upcoming 2025 Annual General Meeting (the "Meeting") will be held virtually at 10:00 a.m.... Read More

Clear regulatory path and strong survival data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) support accelerated strategy to drive shareholder value and partnership opportunities SAN DIEGO and CALGARY, AB , July 29, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced it has... Read More

SAN DIEGO and CALGARY, AB , July 23, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, hosted a key opinion leader (KOL) webinar featuring leading physicians in the fields of oncology and immunotherapy discussing pelareorep's robust clinical data and how it fits in the evolving treatment landscape for pancreatic and gastrointestinal... Read More

SAN DIEGO and CALGARY, AB , July 22, 2025 /CNW/ - Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a leading clinical-stage company specializing in immunotherapy for oncology, received a formal letter (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated July 22, 2025 informing the Company that it has regained compliance with... Read More

Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment Cross-study data show pelareorep increases PD-L1 expression and boosts cytotoxic T-cell activity, priming resistant tumors for checkpoint inhibitors Results reinforce pelareorep's ability to turn cold tumors hot, paving the way for registration-enabling trials SAN DIEGO and... Read More

KOL webinar to take place on July 22, 2025 , at 1:00 p.m. ET SAN DIEGO and CALGARY, AB , July 10, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, announced that it will host a key opinion leader (KOL) webinar to discuss pelareorep in metastatic pancreatic ductal adenocarcinoma (mPDAC) and other gastrointestinal cancers. The... Read More

Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.9% vs. 9.2% historical benchmark Consistent survival benefit compared to standard-of-care chemotherapy in randomized studies in the large HR+/HER2- metastatic breast cancer indication Data from over 1,100 patients across tumor types reveals a favorable, well-understood safety... Read More

SAN DIEGO and CALGARY, Alberta , June 30, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer. Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the $2 billion acquisition of the San... Read More

SAN DIEGO and CALGARY, AB , June 11, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Jared Kelly as Chief Executive Officer and a member of its Board of Directors. Mr. Kelly is a successful biotech executive who has proven expertise in transformative deals and corporate strategy. Most recently,... Read More

Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New analyses confirm that pelareorep primes the TME to allow circulating tumor-infiltrating lymphocytes (TILs) in the blood to attack tumors Pre-existing TIL clones in plasma may correlate positively with tumor shrinkage in pancreatic cancer SAN DIEGO and CALGARY, AB , May 23, 2025 /CNW/ -- Oncolytics Biotech... Read More

American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancers Poster on pelareorep's stimulation of adaptive and innate immunity to be shared at ASCO Annual Meeting Conference call and webcast today at 4:30 p.m. ET to discuss Q1 results and... Read More

Conference call and webcast to take place on Wednesday, May 14, 2025 , at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , May 6, 2025 - Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Wednesday, May 14, 2025 , at 4:30 p.m. ET to discuss a corporate update and financial results for the... Read More

ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients Ongoing updates support potential of pelareorep combination therapies in one of the deadliest and hardest-to-treat cancers SAN DIEGO and CALGARY, AB , April 24, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will present new... Read More

SAN DIEGO and CALGARY, AB , April 10, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered into a share purchase agreement (SPA) with Alumni Capital LP (Alumni), an institutional investor. This partnership will provide Oncolytics with a flexible source of funding, enabling the Company to progress pelareorep toward key... Read More

SAN DIEGO and CALGARY, AB , April 10, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discussed by field-leading key opinion leaders (KOLs) during a recent event hosted by H.C. Wainwright. Martine Piccart, M.D., Ph.D., an Honorary Professor of Oncology at the Université Libre de Bruxelles (ULB) and Scientific Director of... Read More

BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support continued development of pelareorep in these indications, with combination studies ongoing Cash position of $15.9 million provides runway through critical milestones into third quarter 2025 Management hosting conference call and... Read More

Conference call and webcast to take place on Friday, March 7, 2025 , at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Feb. 25, 2025 /CNW/ -- Oncolytics Biotech ® Inc. ( NASDAQ : ONCY ) ( TSX : ONC ), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025 , at 8:30 a.m. ET to discuss a corporate update and financial... Read More

Regulatory progress in pancreatic cancer and recent clinical data presentations in two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, highlight pelareorep's potential impact across a range of tumors Republication of press release issued February 18 th 2025 due to news transmission coverage SAN DIEGO and CALGARY, AB , Feb. 19, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC),... Read More

Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor types SAN DIEGO and CALGARY, AB , Feb. 18, 2025 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in... Read More

SAN DIEGO and CALGARY, AB , Feb. 14, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it received a delinquency notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on February 13, 2025 indicating that the Company is not currently in compliance... Read More

New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1 SAN DIEGO and CALGARY, AB , Jan. 15, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Germany's medical regulatory body, the Paul-Ehrlich-Institute (PEI), has approved the continuation of patient enrollment into Cohort 5... Read More

Promising BRACELET-1 results in HR+/HER2- metastatic breast cancer lay the foundation for potential registration-enabling study and accelerated approval Advancing gastrointestinal cancer pipeline underscores potential for additional registration-enabling studies SAN DIEGO and CALGARY, AB , Dec. 23, 2024 /CNW/ -- Oncolytics Biotech ® Inc. ( NASDAQ : ONCY ) ( TSX : ONC ), a leading clinical-stage company specializing in... Read More

SAN DIEGO and CALGARY, AB , Dec. 18, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO)... Read More

Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without atezolizumab The study will begin with 30 patients, with an option to expand to an additional 34 participants SAN DIEGO and CALGARY, AB , Dec. 3, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in... Read More

BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study Upcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from the modified FOLFIRINOX pancreatic cancer cohort Cash position of $19.6 million as of September 30, 2024 Management hosting... Read More

Conference call and webcast to take place on Tuesday, November 12, 2024 , at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Nov. 11, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Tuesday, November 12, 2024 , at 8:30 a.m. ET to discuss a corporate update and financial... Read More

Conference call and webcast to take place on Tuesday, November 12, 2024 , at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Nov. 11, 2024 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Tuesday, November 12, 2024 , at 8:30 a.m. ET to discuss a corporate update and... Read More

Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval Key milestones in gastrointestinal cancer clinical trials expected in 2025, with potential for new registration-enabling studies SAN DIEGO and CALGARY, AB , Oct. 4, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company... Read More

Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the compelling potential of pelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast cancer Oncolytics Biotech is moving forward to secure funding for a registration-enabling study of pelareorep-based therapy in advanced or... Read More

SAN DIEGO and CALGARY, AB , Sept. 6, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Financial Officer Kirk Look will participate in a fireside chat at the H.C. Wainwright 26 th Annual Global Investment Conference, which is taking place September 9-11, 2024 at the Lotte New York Palace Hotel in New York,... Read More

SAN DIEGO and CALGARY, AB , Aug. 2, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Medical Officer Dr. Thomas Heineman will participate in a fireside chat at Canaccord Genuity's 44 th Annual Growth Conference, which is taking place August 13-15, 2024 at the InterContinental Boston Hotel in Boston, MA.... Read More

Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer On track to report overall survival results from randomized BRACELET-1 breast cancer study in H2 2024 Dosed first patient in new GOBLET study pancreatic cancer cohort; supported by funding from PanCAN Entered into collaboration with GCAR for inclusion of pelareorep in... Read More

Conference call and webcast to take place on Thursday, August 1, 2024 , at 4:30 p.m. ET SAN DIEGO, Calif. and CALGARY, Alberta , July 24, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, August 1, 2024 , at 4:30 p.m. ET to discuss a corporate update and... Read More

Conference call and webcast to take place on Thursday, August 1, 2024 , at 4:30 p.m. ET SAN DIEGO, Calif. and CALGARY, Alberta , July 24, 2024 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, August 1, 2024 , at 4:30 p.m. ET to discuss a corporate update... Read More

Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report overall survival results from the randomized HR+/HER2- metastatic breast cancer BRACELET-1 trial in H2 2024 SAN DIEGO and CALGARY, AB , June 27, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for... Read More

Wayne Pisano , Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer study continues to be expected in H2 2024 Pelareorep combination therapy advancing towards registration-enabling study in pancreatic cancer SAN DIEGO and CALGARY, AB , June 24, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in... Read More

Demonstrating pelareorep's synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefit Funding for the study comes from the US$5 million Therapeutic Accelerator Award from PanCAN SAN DIEGO , and CALGARY, AB , June 20, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology,... Read More

Trial-in-progress abstract highlights new cohort that could expand the company's pancreatic cancer program Pelareorep's ability to expand TILs highlights its immunotherapeutic mechanism of action and potential as a backbone immunotherapy for multiple indications SAN DIEGO and CALGARY, AB , May 24, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy... Read More

SAN DIEGO and CALGARY, AB , May 16, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Wednesday, May 15, 2024. A total of 41.34% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy... Read More

Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy utilized in cohort 1 of the GOBLET study GCAR is launching a new master protocol for pancreatic cancer with the intent to create a registration-enabling pathway for investigational therapies Innovative adaptive design could accelerate registrational study timeline and provide substantial cost savings... Read More

Pelareorep advancing to registration-enabling studies Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer Overall survival data from BRACELET-1 breast cancer study expected in H2 2024 Cash position of $29.6 million provides runway through critical milestones into 2025 Management hosting conference call and webcast today at 4:30 p.m. ET SAN DIEGO and... Read More

US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study Study of modified FOLFIRINOX/pelareorep/atezolizumab (Tecentriq ® ) combination expands existing pancreatic cancer program First patient expected to be enrolled in Q2 2024 SAN DIEGO and CALGARY, AB , May 9, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in... Read More

SAN DIEGO and CALGARY, AB , May 8, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Dr. Matt Coffey , President and Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference, which is taking place May 14-15, 2024 at the InterContinental New York... Read More

Conference call and webcast to take place on Thursday, May 9, 2024 , at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , April 30, 2024 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, May 9, 2024 , at 4:30 p.m. ET to discuss a corporate update and financial... Read More

Conference call and webcast to take place on Thursday, May 9, 2024 , at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , April 30, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, May 9, 2024 , at 4:30 p.m. ET to discuss a corporate update and financial results... Read More

SAN DIEGO and CALGARY, AB , April 25, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the acceptance of two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from May 31 – June 4, 2024 , in Chicago, Illinois . Details on the abstracts and poster presentation... Read More

Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer Overall survival results from the randomized HR+/HER2- metastatic breast cancer BRACELET-1 trial expected in H2 2024 SAN DIEGO and CALGARY, AB , April 11, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for... Read More

SAN DIEGO and CALGARY, AB , April 2, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that President and Chief Executive Officer Dr. Matt Coffey will participate in the Viral Approaches in Oncology panel at Canaccord Genuity's Horizons in Oncology Virtual Conference, which is taking place on April 15, 2024 . Additional details... Read More

SAN DIEGO and CALGARY, AB , April 2, 2024 /PRNewswire/ -- Oncolytics Biotech ® Inc . (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that President and Chief Executive Officer Dr. Matt Coffey will participate in the Viral Approaches in Oncology panel at Canaccord Genuity's Horizons in Oncology Virtual Conference, which is taking place on April 15, 2024 . Additional... Read More

Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with mFOLFIRINOX Impressive objective response rate in GOBLET study anal carcinoma cohort supports enrollment expansion Expecting to report overall survival data from BRACELET-1 breast cancer study in 2024 Cash position of $34.9 million provides runway through critical... Read More

US$5M grant supports study of pelareorep in combination with modified FOLFIRINOX +/- atezolizumab Testing with the most common therapies could facilitate broad use of pelareorep in pancreatic cancer patients SAN DIEGO and CALGARY, AB , March 5, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced it has submitted an amendment to... Read More

Conference call and webcast to take place on Thursday, March 7, 2024 , at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , March 4, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that it will host a conference call and webcast on Thursday, March 7, 2024 , at 4:30 p.m. ET to discuss a corporate update and financial results for the... Read More

Conference call and webcast to take place on Thursday, March 7, 2024 , at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , March 4, 2024 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that it will host a conference call and webcast on Thursday, March 7, 2024 , at 4:30 p.m. ET to discuss a corporate update and financial results for... Read More

SAN DIEGO and CALGARY, AB , Feb. 28, 2024 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that Chief Executive Officer Dr. Matt Coffey will present a corporate overview at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference. The conference is taking place from February 29 - March 2, 2024 , at the Ritz Carlton... Read More

Successful Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion SAN DIEGO and CALGARY, Alberta , Feb. 14, 2024 /CNW/ -- Oncolytics Biotech ® Inc . (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the expansion of enrollment for the anal cancer cohort of the... Read More

SAN DIEGO and CALGARY, AB , Jan. 9, 2024 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Patricia S. Andrews to its Board of Directors (the "Board"). "I am pleased to welcome Pat Andrews to our Board of Directors," said Dr. Matt Coffey , President and Chief Executive Officer of Oncolytics. "Pat's extensive board... Read More

SAN DIEGO , CA and CALGARY, AB , Jan. 4, 2024 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, reported on significant 2023 accomplishments and announced corporate priorities and anticipated clinical development milestones for 2024. Overview : "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer... Read More

Pelareorep induced prominent expansion of pre-existing Tumor Infiltrating Lymphocytes (TILs) in the blood and new TILs in the tumor Data highlights the association between the expansion of existing TILs in the blood and decreased tumor size Results affirm pelareorep's role as an immunotherapy SAN DIEGO and CALGARY, AB , Dec. 7, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage... Read More

Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response SAN DIEGO and CALGARY, Alberta , Nov. 9, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the... Read More

Updated plan follows PanCAN's strategic re-evaluation of the Precision Promise SM Program PanCAN US$5 million grant provides support for new GOBLET mFOLFIRINOX arm to proceed as planned New Phase 3 strategy provides significant value-creation opportunities SAN DIEGO, CA and CALGARY, AB , Nov. 9, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused... Read More

Novel imaging mass cytometry (IMC) technology enables a closer look at tumor microenvironment post-pelareorep/atezolizumab/letrozole treatment Affirms pelareorep's ability to increase PD-L1 positive cells and T cell infiltration in the tumor microenvironment Data will support conduct of registrational program for pelareorep SAN DIEGO, CA and CALGARY, AB , Nov. 3, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX:... Read More

Phase 1/2 survival data from GOBLET pancreatic cancer cohort demonstrates improvements over historical control trials Award and grant funding from Pancreatic Cancer Action Network (PanCAN) provides financial boost and will enable further evaluation of pelareorep in pancreatic cancer Cash position stands at $40.0 million with a projected cash runway through critical milestones, including BRACELET-1 survival data Management... Read More

7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by ≥ 25% T-cell expansion data correlate with tumor response, providing important proof-of-concept SAN DIEGO and CALGARY, AB , Oct. 23, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY),( Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the poster presentation of positive, updated results... Read More

Results met efficacy criteria for enrollment expansion and provide support for pelareorep's mechanism of action SAN DIEGO and CALGARY, AB , Oct. 23, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY), (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the poster presentation of interim results from the Phase 1/2 GOBLET study evaluating a combination treatment of... Read More

Conference call and webcast to take place on Friday, November 3, 2023 , at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Oct. 20, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that it will host a conference call and webcast on Friday, November 3, 2023 , at 8:30 a.m. ET to discuss a corporate update and financial results for the... Read More

Preliminary updated PDAC data show 6-month overall survival rate of 82% Results from pelareorep combination in mCRC met the Stage 1 success criteria SAN DIEGO and CALGARY, AB , Oct. 16, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the publication of two abstracts for posters to be presented during the upcoming European... Read More

Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies BOSTON , SAN DIEGO , and CALGARY, AB , Sept. 26, 2023 /CNW/ -- In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network (PanCAN) today announced Oncolytics Biotech, Inc. (NASDAQ: ONCY) (TSX: ONC) as the recipient of... Read More

SAN DIEGO and CALGARY, AB , Sept. 19, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced its participation in an analyst-led fireside chat at the Cantor Global Healthcare Conference 2023 with Chief Executive Officer Dr. Matt Coffey . The conference is taking place September 26-28, 2023 at the InterContinental Barclay Hotel in New... Read More

CALGARY, AB , Sept. 7, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (" Oncolytics " or the " Company ") (NASDAQ: ONCY) (TSX: ONC) today announced that in connection with the previously announced underwritten public offering of US$15,000,750 (the " Offering ") and the underwriting agreement dated August 1, 2023 (the " Underwriting Agreement "), Leede Jones Gable Inc. (the " Underwriter ") has exercised their option (the "... Read More

SAN DIEGO and CALGARY, AB , Sept. 6, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Executive Officer Dr. Matt Coffey will participate in a fireside chat at the H.C. Wainwright 25 th Annual Global Investment Conference, which is taking place September 11-13, 2023 at the Lotte New York Palace Hotel in New York, NY . Additional details on the fireside chat can be found below. Date:... Read More

Phase 2 data from randomized BRACELET-1 trial in HR+/HER2- metastatic breast cancer showed a near tripling of confirmed ORR, >50% improvement in PFS, and 71% reduction in risk of disease progression Pelareorep selected for inclusion in the Precision Promise SM phase 3 platform trial in pancreatic cancer, designed to accelerate registration path and reduce by ~50% phase 3 costs compared to traditional trial $24.4 million in... Read More

CALGARY, Alberta , Aug. 8, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (" Oncolytics " or the " Company ") (NASDAQ: ONCY) (TSX: ONC) today announced the closing (the " Closing ") of the previously announced underwritten public offering of US$15,000,750 (the " Offering "). An institutional investor was a significant participant in the Offering. The Company intends to use the proceeds from the Offering to continue the advancement... Read More

SAN DIEGO and CALGARY, AB , Aug. 4, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Executive Officer Dr. Matt Coffey will participate in a fireside chat at Canaccord Genuity's 43 rd Annual Growth Conference, which is taking place August 7-10, 2023 at the InterContinental Boston in Boston, MA. Additional details on the fireside chat can be found below. Date: Thursday, August 10,... Read More

Conference call and webcast to take place on Monday, August 14, 2023 , at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Aug. 4, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Monday, August 14, 2023 , at 8:30 a.m. ET to discuss a corporate update and financial results for the second quarter of 2023. Conference Call & Webcast Date: Monday, August... Read More

CALGARY, AB , July 31, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (" Oncolytics " or the " Company ") (NASDAQ: ONCY) (TSX: ONC) today announced that it has entered into an agreement with Leede Jones Gable Inc. as underwriter and bookrunner (the " Underwriter "), pursuant to which the Underwriter has agreed to purchase, on a bought-deal basis, 6,667,000 units (the " Equity Units ") for gross proceeds to the Company of... Read More

Adaptive clinical trial designed to accelerate registration pathways for pancreatic cancer therapies and expected to reduce cost of a Phase 3 study for pelareorep by ~50% compared to a traditional trial If successful, new clinical study expected to support approval of pelareorep in combination with a checkpoint inhibitor, gemcitabine, and nab-paclitaxel in first-line metastatic pancreatic cancer Data presented at SITC 2022... Read More

Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclitaxel vs. 13.3% with paclitaxel monotherapy 12-month progression-free survival rate of 32.8% for pelareorep-paclitaxel compared to 0% for paclitaxel monotherapy and 0% for pelareorep-paclitaxel-avelumab Oncolytics' HR+/HER2- breast... Read More

Key opinion leader webinar to take place on June 5, 2023 at 8:00 a.m. ET SAN DIEGO and CALGARY, AB , May 26, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) announced that it will host a key opinion leader webinar to discuss data from the randomized phase 2 BRACELET-1 trial in HR+/HER2- metastatic breast cancer, which will be featured in an oral presentation at the upcoming American Society of Clinical... Read More

31% week-16 overall response rate and 9.6-month median progression-free survival with pelareorep plus paclitaxel vs. 20% and 6.4 months with paclitaxel alone as of Oct. 2022 ASCO abstract cut-off date Updated data from May 2023 cut-off date will be presented in an oral presentation on June 3, 2023 Oncolytics to advance to registrational study of pelareorep-paclitaxel combination in HR+/HER2- breast cancer SAN DIEGO , and... Read More

SAN DIEGO and CALGARY, AB , May 10, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Tuesday, May 9, 2023. A total of 44% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. On a vote by ballot, the seven nominees proposed by the... Read More

Randomized phase 2 data from BRACELET-1 trial in HR+/HER2- metastatic breast cancer to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Guidance on the registration paths for pelareorep in HR+/HER2- metastatic breast and first-line pancreatic cancer expected in H2 2023 $29.7 million in cash, cash equivalents, and marketable securities as of March 31, 2023 provides projected... Read More

Oral presentation on BRACELET-1 to take place on June 3, 2023 SAN DIEGO and CALGARY, AB , April 26, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract for an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from June 2 – 6, 2023 in Chicago, Illinois and online. "Being selected for an oral presentation at... Read More

SAN DIEGO and CALGARY, AB , April 12, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Medical Officer Thomas Heineman , M.D., Ph.D., will participate in the Viral Immunotherapy – Moving Forward panel at Canaccord Genuity's Horizons in Oncology Virtual Conference, which is taking place virtually on April 20, 2023 . Additional details on the panel presentation can be found below.... Read More

Conference call and webcast to take place on Friday, May 5, 2023 , at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , April 12, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, May 5, 2023 , at 8:30 a.m. ET to discuss a corporate update and financial results for the first quarter 2023. Conference Call & Webcast Date: Friday, May 5, 2023... Read More

Your vote is important no matter how many votes you hold. Vote today Shareholders who have questions or need assistance with voting their shares should contact Oncolytics Biotech Inc.'s strategic advisor and proxy solicitation agent Laurel Hill Advisory Group by telephone at 1-877-452-7184 or by email at assistance@laurelhill.com SAN DIEGO and CALGARY, AB , April 12, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY)... Read More

SAN DIEGO and CALGARY, AB , March 28, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey , President and Chief Executive Officer, will participate in the Novel Mechanisms with Important Readouts panel at Cantor Fitzgerald's The Future of Oncology Virtual Symposium, which is taking place April 3-5, 2023 in a virtual format. Additional details on the panel presentation can be... Read More

Pancreatic cancer program advancing towards registration path supported by phase 1/2 GOBLET data showing a confirmed complete response and 69% objective response rate in advanced/metastatic patients Phase 2 BRACELET-1 trial in HR+/HER2- metastatic breast cancer on track for a randomized data readout in Q2 2023 that will inform the design of a pivotal trial Registration opportunities in breast and pancreatic cancer are... Read More

Conference call and webcast to take place on Friday, March 3, 2023 , at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Feb. 21, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, March 3, 2023 , at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2022. Conference Call & Webcast Date:... Read More

Thirteen of fourteen (93%) evaluable patients achieved disease control, with twelve (86%) showing tumor shrinkage SAN DIEGO and CALGARY, AB , Dec. 8, 2022 /CNW/ -- Oncolytics Biotech ® Inc.'s (NASDAQ: ONCY) (TSX: ONC) Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel... Read More

FDA Fast Track designation granted after presentation at the SITC 37 th Annual Meeting demonstrating 69% objective response rate SAN DIEGO , and CALGARY, AB , Dec. 1, 2022 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab,... Read More